

LISTING OF THE CLAIMS

This listing of claims will replace all prior versions, and listings of claims in the application:

1. (Previously Presented) A dispersion, comprising:
a solids content of 10-70% by weight comprising
 - a) from 90 to 99% by weight of a methacrylate copolymer comprising at least 90% by weight of a (meth)acrylate monomer containing at least one neutral radical and having a glass transition temperature T_g of from -20°C to +20°C as determined by the DSC method, and
 - b) 1-10% by weight of a nonionic emulsifier having an HLB of from 15.2 to 17.3.
2. (Previously Presented) The dispersion according to Claim 1, wherein the methacrylate copolymer comprises from 20 to 50% by weight of methyl methacrylate, and from 80 to 50% by weight of ethyl acrylate.
3. (Previously Presented) The dispersion according to Claim 1, wherein the nonionic emulsifier is selected from the group consisting of ethoxylated fatty acid ester, ethoxylated fatty acid ethers, ethoxylated sorbitan ethers, ethoxylated alkyl-phenols, glycerol esters, glycerol sugar esters, wax derivatives and mixtures thereof.
4. (Previously Presented) The dispersion according to Claim 1, wherein the nonionic emulsifier is selected from the group consisting of polyoxyethyleneglycerol monolaurate, polyoxyethyleneglycerol monostearate, polyoxyethylene-20-cetyl stearate,

polyoxyethylene-25-cetyl stearate, polyoxyethylene (25)-oxypropylene monostearate, polyoxyethylene-20-sorbitan monopalmitate, poly-oxyethylene-16-tert-octylphenol, polyoxyethylene-20-cetyl ether, polyethylene glycol(1000) monocetyl ether, ethoxylated castor oil, polyoxyethylene sorbitol-lanolin derivatives, polyoxyethylene(25)propylene glycol stearate, polyoxyethylenesorbitol esters, polyoxyethylene-20-sorbitan monopalmitate, polyoxyethylene-16-tert-octylphenol, polyoxyethylene-20-cetyl ether and mixtures thereof.

5. (Previously Presented) A process for preparing the dispersion claimed in Claim 1, comprising: emulsion polymerizing said (meth)acrylate monomer.

6. (Previously Presented) A pharmaceutical composition, comprising:
the dispersion as claimed in Claim 1, and
a pharmaceutically active substance.

7. (Previously Presented) The pharmaceutical composition as claimed in Claim 6, wherein said pharmaceutically active substance comprises an active substance selected from the group consisting of morphine, morphine derivatives, tramadol, acetylsalicylic acid, diclofenac, indomethacin, lonazolac, ibuprofen, ketoprofen, propyphenazone, naproxen, paracetamol, flurbiprofen, dimetindene, quinidine, metoprolol, propranolol, oxprenolol, pindolol, atenolol, metoprolol, disopyramide, verapamil, diltiazem, gallopamil, nifedipine, nicardipine, nisoldipine, nimodipine, amlodipine, theophylline, salbutamol, terbutaline, ambroxol, aminophylline, choline theophyllinate, pyridostigmine, piretanide, furosemide, pentoxifylline, naftidrofuryl, buflomedil, xanthinol nicotinate, bencyclane, allopurinol, norephedrine, chlorphenamine, isosorbide mononitrate, isosorbide dinitrate, glycerol trinitrate, molsidomine, bezafibrate, fenofibrate, gemfibrozil, cerivastatin, prava-statin,

fluvastatin, lovastatin, atorvastatin, simvastatin, xanthinol, methoclopramide, amitriptyline, dibenzepine, venlafaxine, thioridazine, oxazepam, lithium, nitrofurantoin, dry plant extract, diprophylline, ascorbic acid, potassium, pharmaceutical salts thereof and mixtures thereof.

8. (Previously Presented) A pharmaceutical composition, comprising:
an active pharmaceutical substance and the dispersion as claimed in Claim 1,
wherein said active pharmaceutical substance is bound or coated with said dispersion.
9. (Previously Presented) A method for coating a pharmaceutical composition,
comprising:
encapsulating the pharmaceutical composition with the dispersion claimed in Claim 1.
10. (Previously Presented) The dispersion according to Claim 1, wherein the
methacrylate copolymer comprises from 20 to 50% by weight of methyl methacrylate and
from 80 to 50% by weight of ethyl acrylate and from 0 to 10% by weight of methacrylic acid.
11. (Previously Presented) The dispersion according to Claim 1, wherein the
nonionic emulsifier is polyoxyethylene-25-cetyl stearate.
12. (Previously Presented) The pharmaceutical composition claimed in Claim 7,
wherein said pharmaceutical salts are potassium salts.
13. (Previously Presented) The dispersion as claimed in Claim 1, wherein said
(meth)acrylate monomer contains C₁ to C₄ alkyl radicals.

14. (Previously Presented) The dispersion as claimed in Claim 1, wherein said (meth)acrylate monomer is methyl methacrylate, ethyl acrylate, methyl acrylate or mixtures thereof.

15. (Previously Presented) The dispersion as claimed in Claim 1, wherein not more than 10 % by weight of said (meth)acrylate monomers contains an anionic radical.

16. (Previously Presented) The dispersion as claimed in Claim 1, wherein said copolymer comprises methacrylic acid.

17. (Previously Presented) The dispersion as claimed in Claim 1, wherein said emulsifier is polyoxyethylene-25-cetyl stearate, polyoxyethylene-20-sorbitan monopalmitate, polyoxyethylene-16-tert-octylphenol, polyoxyethylene-20-cetyl ether or mixtures thereof.

18. (Previously Presented) A coating agent, comprising:
the dispersion as claimed in Claim 1.

19. (Previously Presented) The dispersion according to claim 1, wherein said emulsifier does not crystallize after drying said dispersion.